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Recombinant Vgr-1/BMP-6-expressing Tumors Induce Fibrosis 
and Endochondral Bone Formation In Vivo 
Stephen E. Gitelman,** Michael S. Kobrin,** Jian-Qin Ye,** Alfredo R. Lopez,1 Angela Lee,** 
and Rik Derynck*§ll 
Departments of * Pediatrics, * Growth and Development, and § Anatomy, II Programs in Cell Biology and Developmental Biology, 
and I Hematology/Oncology Section at Veterans Administration Medical Center, University of California t San Francisco, 
San Francisco, California 94143; and **Genentech, Inc., South San Francisco, California 94080 
Abstract. Members of the TGF-/~ superfamily appear 
to modulate mesenchymal differentiation, including the 
processes of cartilage and bone formation. Nothing is 
yet known about the function of the TGF-#-related 
factor vgr-1, also called bone morphogenetic protein-6 
(BMP-6), and only limited studies have been con- 
ducted on the most closely related factors BMP-5, os- 
teogenic protein-1 (OP-1) or BMP-7, and OP-2. Be- 
cause vgr-1 mRNA has been localized in hypertrophic 
cartilage, this factor may play a vital role in en- 
dochondral bone formation. We developed antibodies 
to vgr-1, and documented that vgr-1 protein was ex- 
pressed in hypertrophic cartilage of mice. To further 
characterize the role of this protein in bone differentia- 
tion, we generated CHO cells that overexpressed 
recombinant murine vgr-1 protein. Western blot analy- 
sis documented that recombinant vgr-1 protein was 
secreted into the media and was proteolytically 
processed to yield the mature vgr-1 molecule. To as- 
sess the biological activity of recombinant vgr-1 in 
vivo, we introduced the vgr-l-expressing CHO cells 
directly into the subcutaneous ti sue of athymic nude 
mice. CHO-vgr-1 cells produced localized tumors, and 
the continuous ecretion of vgr-1 resulted in tumors 
with a strikingly different gross and histological ap- 
pearance as compared to the parental CHO cells. The 
tumors of control CHO cells were hemorrhagic, 
necrotic, and friable, whereas the CHO-vgr-1 tumors 
were dense, firm, and fibrotic. In contrast with control 
CHO tumors, the nests of CHO-vgr-1 tumor cells were 
surrounded by extensive connective tissue, which con- 
tained large regions of cartilage and bone. Further 
analysis indicated that secretion of vgr-1 from the 
transfected CHO tumor cells induced the surrounding 
host mesenchymal cells to develop along the en- 
dochondral bone pathway. These findings suggest that 
endogenous vgr-1 acts as an osteoinductive factor dur- 
ing endochondral bone formation. 
U 
RtN6 development, a variety of growth and differen- 
tiation factors influence cell proliferation, differen- 
tiation, and migration. Several secreted peptide 
growth factors have been shown to mediate these processes, 
exerting their activities locally in an autocrine or paracrine 
fashion (reviewed in reference 20). The TGF-B superfam- 
ily represents one group of such factors that is particularly 
important in modulating mesenchymal differentiation (re- 
viewed in references 10, 41). This family of factors influ- 
ences pluripotent progenitor cells to differentiate into fibro- 
blasts, adipocytes, myoblasts, chondrocytes, or osteoblasts. 
Correctly coordinated differentiation of mesenchymal cells 
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into such cell lineages may depend on a defined spatial and 
temporal expression pattern for specific TGF-B-related fac- 
tors (for examples, see references 14, 31). 
One aspect of mesenchymal differentiation that remains 
incompletely characterized includes endochondral bone for- 
marion, bone fracture healing, and ectopic bone formation, 
all of which proceed through a similar developmental cas- 
cade. In these processes, mesenchymal precursor cells first 
differentiate into chondrocytes and give rise to a cartilage 
template. Within the center of this template, the chondro- 
cytes enter a proliferative phase, then mitosis arrests and the 
cells undergo hypertrophy. The hypertrophic cartilage 
mineralizes in the later stages of maturation, and is eventu- 
ally invaded by blood vessels and replaced by a mineralized 
bone matrix. This bone matrix is deposited by osteoblasts, 
which also have differentiated from mesenchymal progenitor 
cells. Recent evidence implicates TGF-~ superfamily mem- 
bers as playing a central role in this complex developmental 
process (reviewed in references 10, 55). 
The TGF-B superfamily consists of a growing number of 
homologous, ecreted, isulfide-bonded dimers (reviewed in 
© The Rockefeller University Press, 0021-9525/94/09/1595/15 $2.00 
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references 10, 41). These proteins can be further subdivided 
into several groups, based on sequence homology. One of 
these groups consists of the three "I'GF-/3 isoforms, TGF-/31, 
-/Y2, and -/~3. Other distinct groups include the activins, in- 
hibins, and Mtillerian inhibitory substance. However, by far 
the largest group comprises the bone morphogenetic pro- 
teins (BMPs) ~, Xenopus vg-1, Drosophila decapentaplegic 
(dpp), and the more recently cloned polypeptides nodal (59), 
dorsalin (3), vgr-2 (22), and growth/differentiation factors 
(GDF)-I (27) and GDF-3 (33). This group has been referred 
to as the decapentaplegic/vg-l-related proteins (DVR) (30). 
The TGF-~ superfamily, and especially the DVR group, 
appears to be of considerable importance inbone and carti- 
lage development. Several members of this superfamily have 
been localized during intramembranous and endochondral 
bone formation, and they are expressed in a spatially and 
temporally distinct but overlapping pattern in the differen- 
flating tissue (for an example, see reference 31). The proteins 
that have been best characterized in terms of their osteoin- 
ductive activity are the subgroup consisting of BMP-2 and 
BMP-4 (reviewed in reference 55), which bear closest ho- 
mology with the decapentaplegic complex protein dpp of 
Drosophila (38). BMP-2 and BMP-4 have the ability to in- 
duce osteoblastic differentiation i  vitro and ectopic bone 
formation when injected intramuscularly (for examples, see 
references 6, 17, 18, 24, 49, 51, 56, 57), and are at least par- 
tially responsible for the osteoinductive activity originally 
purified from bone (40, 46). 
The largest subgroup of DVR proteins consists of BMP-5 
(5), vgr-1 (29) or BMP-6 (5), osteogenic protein-1 (OP-1) 
(36) or BMP-7 (5), and OP-2 (37), all of which have a high 
degree of homology to the ancestral 60A protein in Drosoph- 
i/a (12). Although BMP-7 has been shown in an initial study 
to induce bone formation in vivo (43) and osteoblastic and 
chondrocytic differentiation i vitro (1, 43), little is currently 
known about he functions of the other members of this sub- 
group and their expression patterns during mammalian de- 
velopment. To define the function of this subgroup in mesen- 
chymal differentiation and especially during endochondral 
bone formation, we have selected vgr-l/BMP-6 as a proto- 
type for our studies. This eDNA was originally isolated from 
a murine embryonic eDNA library and was named vgr-l, 
based on its homology with Xenopus vg-1 (29). The human 
and bovine homologues of vgr-1 were subsequently cloned 
from bone and were named BMP-6 (5), but no bone mor- 
phogenetic a tivity has been reported for this protein. Exten- 
sive in situ hybridization analyses have localized vgr-1 
mRNA expression to the central nervous ystem, to various 
epithelial structures including the suprabasal layer of the 
epidermis, and, of most relevance to the current studies, to 
hypertrophic cartilage (21, 31). Notably, it is the only mem- 
ber of the TGF-B superfamily that has been localized to 
hypertrophic cartilage, and, as such, vgr-1 protein could be 
involved in the maturation of hypertrophic cartilage and/or 
stimulation of osteoblastic differentiation. However, in a re- 
cent immunohistochemical localization study, vgr-1 protein 
was not detected in hypertrophic artilage, suggesting that 
there may be translational inhibition of vgr-1 expression in 
the latter tissue (50). 
1. Abbreviations used in this paper: BMPs, bone morphogenic proteins; 
dhfr, dihydrofolate r ductase; dpp, decapentaplegic; DVR, dpp/vg-l-related 
proteins; GDF, growth/differentiation factors; OP-1, osteogenic protein-l. 
In this study, we developed antibodies to vgr-1, and showed 
that vgr-1 protein was indeed expressed in hypertrophic carti- 
lage. Furthermore, we generated transfected CHO cells that 
produced recombinant vgr-1 protein, and showed that the 
protein was proteolytically processed and secreted by these 
cells. Injection of the vgr-l-expressing CHO cells into the 
subcutaneous ti sue of nude mice resulted in tumors with 
fibrosis and regions of cartilage and bone. Further analysis 
indicated that vgr-1 secreted by the injected CHO cells in- 
duced the surrounding host mesencbymal cells to differenti- 
ate into chondrocytes and osteoblasts. Our data indicate that 
vgr-1 may represent a vital factor for differentiation along the 
endochondral bone cascade. 
Materials and Methods 
Construction of the ~,r-I Expression Vector 
To obtain the vgr-I gene, a 780-bp SmaI fragment from the 5' end of the 
vgr-I eDNA was used as a probe to screen a mouse genomic library in h 
Charon 4A under high stringency. The library was plated at 50000 
pfu/plate, and '~1 x 10 ~ clones were screened. Candidate positive clones 
from duplicate filter lifts were purified through subsequent rounds of 
screening. Library plating, probe labeling, phage lifts, and filter hybridiza- 
tions were carried out as described previously (11). Restriction fragments 
of one such phage were suboloned into pUC219 for further mapping, and 
subsequently sequenced inM13 through standard ideoxy sequencing (44) 
with Sequenase (United States Biochemical Corp., Cleveland, OH). This 
analysis led to the identification of the first coding exon of the vgr-1 gene. 
For expression studies, the original vgr-1 eDNA (29) was suboloned into 
the BamHI-EcoRI site of the pRK7 expression vector (53). To generate he 
composite full-length vgr-1 eDNA expression vector, we replaced the 5' 
coding sequence of the original eDNA (29) with an 851-bp BamHI/BspHI 
genomic fragment that contained 5'flanldn~ DNA and the first coding exon, 
and then performed a three-part ligation in which this fragment was ligated 
with the downstream 1551-bp BspHI/EcoRI 3' vgr-1 eDNA fragment and 
the pRK 7 expression vector that had been digested with BamHI and EcoRI. 
The resultant plasmid was named pRK7-vgr-1. 
Cell Culture and Transfection 
CHO cells deficient in the synthesis of dihydrofolate rednctase (dhfr) (47) 
were propagated in F-12 Ham's nutrient mix (Gibco BRL, Gaithersbuvg, 
MD) and supplemented with 10% fetal calf serum (Hyclone Laboratories, 
Logan, UT), 100 U/ml penicillin, and 100 #g/ml streptomycin (both from 
Giboo BRL). Cells were tmmfeoed with 15 t~g of the pRK7-vgr-1 expres- 
sion vector and 300 ng of pSV-dhfr DNA (45) using the calcium-phosphate 
precipitation method (52). Cells were incubated for 4 h, the medium was 
removed, and the cells were exposed to a 15% glycerol shock for 1 min. 
After rinsing twice with PBS, the cells were incubated insupplemented me- 
dia until they reached confluence, at which time they were split 1:8 and 
selected in media lacking glycine, hypoxanthine, and thymidine, and sup- 
plemented with 5 % dialyzed fetal calf serum. Individual clones were 
selected after 3 wk, and, after expansion, were screened by Northern blot 
analysis for expression ofvgr-1 mRNA. The integrated plasmid sequences 
of several positive clones were amplified through culturing in gradually in- 
creasing levels of methotrexate, up to 500 nM, thereby generating the CHO- 
vgr-1 cells. 
Transient transfections of pRK7-vgr-1 into 293 cells were performed as 
described previously (15). 
RNA Preparation and Northern Blot Analysis 
Total RNA was prepared from cultured cells by lysis with guanidinium 
isothiocyanate, phenol extraction, and ethanol precipitation, according to 
standard protocols (7). The RNA was quantitated spectrophotometrically 
at 260 nm, and was stored at -70°C until use. For Northern blot analysis, 
20/~g of total RNA was electrophoresed in a formaldehyde gel in MOPS 
buffer and transferred to nylon membranes (Gene Screen; New England 
Nuclear, Boston, MA). The vgr-1 eDNA probe corresponded to the 2.4-kb 
BamHI/EcoRI eDNA from the pRK7-vgr plasmid, and was radiolabeled 
using the [32P]dCTP random primer labeling method (Oligolabeling Kit; 
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Pharmacia, Uppsala, Sweden). Hybridization, washing, and autoradiogra- 
phy were performed as described previously (14). 
Cell Growth Rate 
CHO or transfected CHO-vgr-1 cells were rinsed with PBS, trypsinized in 
0.25% trypsin with 0.02% versene, and diluted in standard media. The cell 
number was determined using a Coulter counter (Coulter Corp., Hialeah, 
FL), and 10,000 cells were plated per well on 24-well plates. The cells were 
grown in standard media with 10% fetal calf serum. FOr analysis of growth 
rate in the presence of serum, the wells were rinsed, trypsinized, and 
counted at regular intervals tarting 12 h after initial plating. For each time 
point, three separate wells of cells were individually counted three times, 
and the cell number was then averaged. FOr analysis of growth rate in the 
absence of sernm, the freshly plated cells were grown in 10% fetal calf se- 
rum for 24 h, then the cells were rinsed three times with PBS and subse- 
quently grown in media supplemented with insulin, transferrin, and 
selenium (GMS-G supplement; Gibco-BRL). The cells were again grown 
in triplicate for each time point, and were first counted 24 h after the serum 
had been withdrawn. 
Antibody Production 
Oligopeptides were synthesized corresponding to the deduced murine pro- 
tein sequence at amino acids 141-157 for the pro region antibody and 
392-407 for the mature region antibody (see Fig. 2). No similar sequences 
are present in BMP-5 and BMP-7, and therefore no crossreactivity was ex- 
pected between the vgrol antibodies and these BMPs. An additional cysteine 
residue was added to the amino terminus of each oligopeptide. The peptides 
were coupled to keyhole limpet hemocyanin according to the method of 
Green et al. (16), and were then mixed in Freund's adjuvant and injected 
into rabbits (Caltag Laboratories, Inc., South San Francisco, CA). Two 
animals were injected with each antigen. The initial injection consisted of 
150/tg in Freund's adjuvant with subsequent booster doses of 100/tg 3 and 
4' wk from the initial injection. The first bleed occurred at 5 wk from the 
initial injection. A 100-~g injection was given after that bleed, and follow- 
up bleeds and injections were each performed at weekly intervals for the 
next 2 wk, and with a last bleed 1 wk later. There was a 2-wk rest period, 
then weekly booster injections for 2 wk, followed by a repetition of the 
above cycle. Antisera was stored at -20°C until use. 
Whole antisera was used for Western blot analysis at the dilutions noted 
below. FOr immunohistochemistry, the antisem were first purified by pas- 
sage over the appropriate antigen affinity column. The columns were con- 
structed by coupling of the synthetic oligepeptides toAffigel-10 (Bio Red, 
Laboratories, Richmond, CA) according to manufacturer's in tructions. 
The antisera was purified by mixing with an equal volume of 0.1 M PBS 
(pH 7.2) and loading onto the appropriate affinity column that had been 
preequilibrated with this buffer. The column was washed with PBS until the 
eluant achieved a baseline reading at OD2som. The specific anti-vgr-1 anti- 
bodies were then eluted with 40 mM diethylamine (pH 11.4), and exchanged 
into PBS buffer by passage over a YM-10 membrane (Amicon Corp., 
Beverly, MA). 
Western Blot Analysis 
Conditioned media was collected from CHO or CHO-vgr-1 transfectants 
grown in media in the absence of serum for 24 h. 200-~1 aliquots were 
lyophilized to dryness, and were resusponded insample buffer under educ- 
ing conditions with 5 %/~-mercaptoethanol. After SDS-PAGE, the samples 
were Uunsferred to nitrocellulose. Immunoblotting was performed with the 
enhanced chemiluminesence kit (Amersham Corp., Arlington Heights, IL) 
according to manufacturer's ecommendations. Whole antisera directed 
against the precursor oligopeptide were used at a 1:1000 dilution, and that 
derived from the mature oligopeptide was used at a 1:250 dilution. Incuba- 
tions with the antibodies were performed overnight at 4°C. 
Injections into Nude Mice 
Homozygous nude, athymic 30-g female mice were obtained from Charles 
River Laboratories (Wilmington, MA). 5 × 106 CHO or CHO-vgr-1 cells 
were injected into the right paraspinous area in the lower lumbar egion. 
Cells were prepared for injection by trypsinization, multiple washes with 
PBS, and resuspension i  0.5 ml of serum-free media per sample. The 
animals were fed ad libitum and monitored three times per week for the ap- 
pearance of solid tumors. When the tumors reached 4 cm in largest di- 
ameter, or by 4 wk, the animals were euthanized, and the tumors were 
resected. Portions of the tumors were fixed in 4% paraformaldehyde and 
embedded inparaffin. The remainder were placed in Tissue Tek OCT com- 
pound (Miles Inc., Elkhart, IN) and snap frozen in liquid N2. 
Histochemistry and Immunohistochemistry 
5-/an paraffin sections were used for all histocbemical nalyses, and all 
staining was performed according to standard procedures (8). 
For immunocytochemistry, cells were grown on tissue culture chamber 
slides (Nunc Inc., Naperville, IL) to 80% confluence, washed with PBS, 
fixed in methanol for 10 min, and then stored at -70°C. After several PBS 
rinses, endogenous peroxidase activity was quenched with 0.3% H202 in 
10% methanol for 20 min. The slides were again rimed in PBS and blocked 
with 3 % BSA in PBS for 30 min at room temperature. The primary antibod- 
ies were then applied and incubated overnight at 4°C. The affinity-purified 
vgr-1 precursor antibody was used at a 1:50 dilution (8/~g/mi). After washes 
with PBS-0.1% Tween 20, anti-rabbit IgG horseradish peroxidase (Amer- 
sham Corp.) was applied at a 1:1000 dilution for 60 rain at room tempera- 
ture. After further washes, 3-amino-9-ethylcarbazole (AEC) substrate 
(Dako Co., Carpinteria, CA) was added for 5 to 10 minutes, and then the 
slides were washed in de-ionized H20, counterstalned with bematexylin, 
and washed with tap H20. 
For analysis of vgT-1 expression i  histological sections, we collected 
mice from gestational day 18.5 embryos, fixed the tissue in 4% parafor- 
maldehyde for 30 minutes, and used 5 ~m sections for immunostaining. The 
afffiulty-purified mature vgr-I antibody was used at a 1:50 dilution (6 ~g/ml). 
FOr analysis of the tumors, we used sections from tumors that had been snap 
frozen in liquid N2 following embedding in Tissue Tek OCT Compound. 
The collagen type I antibody was an affinity purified goat antibody raised 
against human and bovine antigens, and the collagen type II antibody was 
an afffiulty-purified antibody directed against the bovine antigen (both anti- 
bodies from Southern Biotechnulogies, Inc., Birmingham, AL). Both 
antibodies were used at dilutions of 1:1,500. The monoclonal routine os- 
teocalcin antibody was purchased from Biomedical Technologies, Inc. 
(Stoughton, MA), and was used at a 1:200 dilution. 
In Situ Hybridization 
To evaluate the expression of dihydrofolate reductase, we used the 548-bp 
BamHI/BgilI fragment from the 3' untranslated region of the hepatitis B sur- 
face antigen gene, which had been incorporated into the 3' region of the di- 
hydrofolate reductase expression unit (45). This fragment was cloned into 
the Bluescript vector (Stratagene, La Jolla, CA), and sense and antisense 
riboprobes were generated with [35S]UTP and T3 and T7 RNA polymer- 
ases, respectively, according to the suppliers protocols (Promnga Corp., 
Madison, WI). 
Frozen sections of 5 pm were cut onto "probe-un plus" microscope slides 
(Fisher Scientific, Pittsburgh, PA), and stored at -70°C. The sections were 
fixed in paraformaldehyde, acetylated, and prehybridized ssentially as de- 
scribed previously (34). Prehybridization was performed at 50°C in hybrid- 
ization buffer for 1 h, and then the solution was removed and replaced with 
the same buffer containing 1 × 106 cpm of riboprobe, and incubated for 
16 h at 50°C. Posthybridization washes and RNase treatments were carried 
out as noted previously (34). After washes, the slides were dehydrated in 
increasing concentrations of ethanol with 0.3 M ammonium acetate, air 
dried, and dipped into Ilford Nuclear Research Emulsion (Cheshire, United 
Kingdom). Sections were exposed in fight safe boxes at 4°C for 6 d, and 
then developed in D-19 developer (Eastman Kodak, Rochester, NY). The 
slides were counterstained in Harris' hematoxylin, and then analyzed under 
bright-field and dark-field microscopy. 
Results 
Vgr-1 Protein is Expressed inHypertrophic Cartilage 
Previous in sire hybrid iTCtion studies have documented ex- 
pression of vgr-1 mRNA in the central nervous system, vari- 
ous epithelial structures including the suprabasal layer of 
skin, and hypertrophic artilage (21, 31). Wall et al. recently 
developed an antibody directed against he precursor egion 
of the murine vgr-1 protein, and subsequent immuno- 
histochemical analysis in the developing mouse confirmed 
the presence of vgr-1 protein in the central nervous system 
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and various epithelial structures (50). However, this anti- 
body failed to detect vgr-1 protein expression i hypertrophic 
cartilage and in some cell lines that express vgr-1 mRNA, 
suggesting that there was translational control of vgr-1 ex- 
pression. Thus, before proceeding with our studies on the 
role of vgr-1 in endochondral bone formation, we had to de- 
termine ifvgr-1 protein was even present in hypertrophic car- 
tilage. Towards this end, we developed polyelonal ntibodies 
that specifically recognized both the precursor and mature 
portions of the murine vgr-1 protein. 
No purified vgr-1 protein was yet available for antibody 
production. Instead, we synthesized two oligopeptides from 
the deduced murine vgr-1 cDNA sequence for use as im- 
munogens. These peptides were selected from regions that 
have no similarity with the corresponding sequences of the 
most closely related factors BMP-5 and -7 (5), and thus the 
resultant antibodies hould not cross-react with any related 
DVR-like factor. Oligopeptides corresponding to amino 
acids 141-157 in the precursor and 392-407 in the mature 
portion of the vgr-1 protein (see Fig. 2) were synthesized, 
coupled to keyhole limpet hemocyanin, and were then used 
as immunogens in rabbits. Antisera exhibited high titers in 
ELISA assays with these peptides, and reacted in Western 
blot assays with recombinant vgr-1 protein synthesized by 
transfected CHO ceils (see below). The whole antisera were 
then affinity purified using the appropriate immunogenic 
oligopeptide coupled to Affigel as an affinity matrix, and 
they yielded antibodies uitable for immunohistochemical 
analyses of vgr-1 expression. 
Immunostaining using the antibody raised against he ma- 
ture, carboxy-terminal portion of the protein detected vgr-1 
protein in the suprabasal layer of the epidermis (see Fig. 1, 
A and B), as described previously (50). In addition, and of 
importance to our study, we detected vgr-1 protein in hyper- 
trophic cartilage (Fig. 1, A and C). This staining was pre- 
dominantly in the extracellular matrix surrounding the 
hypertrophic hondroeytes. Furthermore, vgr-1 protein lo- 
calized specifically to regions of hypertrophic artilage that 
had undergone mineralization, as shown by corresponding 
von Kossa staining in an adjacent tissue section (Fig. 1 D). 
Thus, vgr-1 protein appeared in the latter stages of hyper- 
trophic cartilage differentiation. The negative control, per- 
formed with substitution of rabbit IgG as the primary anti- 
body, resulted in no such staining pattern, demonstrating the 
specificity of the vgr-1 immunostaining. When using the an- 
tibody raised against he precursor segment peptide, vgr-1 
protein was again detected in skin, but only ,~ery weak im- 
munostaining was apparent in hypertrophic cartilage (data 
not shown). 
Expression of Recombinant Vgr-1 Protein by 
Tmnsfected Cells 
The expression of vgr-1 in the hypertrophic cartilage sug- 
gested that it may play a role in the maturation of the hyper- 
trophic ehondroeytes and/or may stimulate new bone forma- 
tion. However, to date, no natural vgr-1 protein has been 
purified, and thus nothing is known about its physiological 
activities. Therefore, to determine the role of this factor in 
endoehondral bone formation, it was necessary to first pro- 
duce recombinant vgr-I protein. 
Initially, the published vgr-1 eDNA (29) was inserted 
downstream ofthe cytomegalovirus promoter in the expres- 
sion vector pRK7. However, transfections of this expression 
vector into 293 cells did not result in detectable vgr-1 protein 
expression. Inspection of the predicted vgr-1 polypeptide s - 
quence showed that the NH2-terminal sequence did not 
comply well with the consensus rules of von Heijne for sig- 
nal peptides (48), and we suspected that our eDNA clone 
was partial length. We subsequently screened a murine 
genomic library with a 5' vgr-1 eDNA probe, and identified 
an upstream exon that contained the 5' untranslated region, 
a translational initiation consensus sequence (26), and a ca- 
nonical signal peptide sequence (48). Primer extension ex- 
periments, using RNA from PYS cells, verified that this se- 
quence represented the 5' end of the vgr-1 mRNA (Kobrin, 
M. S., unpublished data). Furthermore, the polypeptide se- 
quence deduced from this genomic fragment now had a high 
degree of sequence similarity with the NH2 terminus of bo- 
vine BMP-6 (5). In retrospect, we believe that the different 
5' end in the published mouse vgr-1 sequence (29) resulted 
from a eDNA artifact hat is likely related to the high G-C 
content of this sequence. We then constructed a composite 
vgr-1 expression vector in pRK7 by ligating a 5' 851-bp 
BamHI-BspHI genomic fragment onto the corresponding 
downstream vgr-1 eDNA fragment (29). Transient ransfec- 
tions of the pRK7-vgr-1 plasmid into 293 cells and metabolic 
labeling of the proteins now resulted in the appearance ofan 
overexpressed protein consistent in size with the vgr-1 pro- 
tein (data not shown). The full-length cDNA sequence en- 
coding the 510-amino acid murine vgr-1 polypeptide is
shown in Fig. 2. 
To produce a stable source of recombinant vgr-I protein, 
we cotransfected pRK7-vgr-1 and a dihydrofolate reduetase 
expression plasmid into CHO ceils, selected several clones 
expressing high levels of vgr-1 mRNA, and amplified its ex- 
pression in the presence of increasing concentrations of 
methotrexate. As shown in Fig. 3 A, Northern blot analysis 
revealed ahigh level of vgr-1 mRNA in one such clone grown 
in 500 nM methotrexate. In contrast, CHO cells transfected 
with dihydrofolate reductase alone did not express vgr-1 
mRNA. Immunostaining using the vgr-1 antiserum also 
showed specific staining of the vgr-1 mRNA-overproducing 
CHO-vgr-1 cells, indicating the synthesis of vgr-1 protein 
(Fig. 3 C). The parental CHO cells exhibited no such stain- 
ing, again indicating lack of vgr-1 expression. 
To assume biological activity, members of the TGF-B su- 
perfamily must enter the secretory pathway and undergo a
proteolytic cleavage that separates the precursor region from 
the biologically active carboxy terminal domain. To deter- 
mine if such processing occurs in the CHO-vgr-1 stable 
transfectants, we collected conditioned media produced by 
these cells and performed Western blot analyses using our 
vgr-1 antisera (Fig. 3 B). After denaturing el electrophore- 
sis under educing conditions and Western analysis, each an- 
tiserum recognized two protein bands from the media of 
transfected cells, but not of the nontransfected cells. The 
larger protein band had a size of "~69 kD, and it reacted in 
Western blots with antisera raised against both the precursor 
and mature vgr-1 segments. This band most likely cor- 
responded to the uncleared vgr-1 precursor polypeptide, 
given its dual antibody reactivity and its size. Two lower pro- 
tein bands were seen as well: a 46-kD protein that reacted 
only with the antibody specific for the vgr-1 precursor seg- 
ment, and a 23-kD protein that reacted with the antibody for 
mature vgr-1. These proteins thus corresponded to the two 
The Journal of Cell Biology, Volume 126, 1994 1598 
Figure L Vgr-1 protein expression in skin and hypertrophic cartilage. Forelimbs from 18.5-d gestation mice w re stained with affinity- 
purified antibody directed against the mature portion of vgr-1. (A) xl0 view showing v r-1 expression in both suprabasal layer ofepithelium 
(arrows) and hypertrophic cartilage (center offigure). Bar, 200/zm (B) x20 view of the skin showing localization of vgr-1 to suprabasal 
layer of epithelium. (C) x20 view of vgr-1 expression i hypertrophic cartilage (center). (D) Section adjacent to hat used for C, with 
von Kossa stain (black) indicating areas of mineralization, and counterstained with nuclear fast red. (E) Negative control, where nonspecific 
IgG is used as the primary antibody. 
cleavage products expected after proteolytic processing of 
the vgr-1 precursor. These cells secreted ~2 #g/ml per 24 h 
of the recombinant factor, and based on these Western a al- 
yses, x,50% of the secreted protein had been proteolytically 
processed. The 69- and 46-kD bands each migrated as a sub- 
tie doublet (Fig. 3 B), which was most apparent in lower per- 
centage polyacrylamide g ls (data not shown). This may 
have been caused byvariations in glycosylation. 
Effects of vgr-1 on CHO Cells in Culture 
To determine the effect of vgr-1 overexpression  these 
cells, we characterized changes in morphology, growth rate, 
and collagen synthesis. No significant difference in cell size, 
shape, or adherence was noted between CHO and CHO-vgr-1 
cells (Fig. 3 C). However, in comparison with the parental 
CHO cells, CHO-vgr-1 cells had a significantly slower rate 
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1: gat  cc tggcggtogcggcgtcgt  c t  c t  tc tccacccgggct  te tgggccacccgcggatgaccat  gagagataaggact  gagtgccagaa  
91:  aagggaagagagcccgcagagaggt  gcgggggct  gcacactccgagggaacagcat~agagatccggcct  agct  cogccgctcgaagac  
181:  tag  a ggg  o c co  gc  gg  gg  ga  agcc  gggc  t g ggaggQ g&f I~)CCCG~. . ,GCTGG~IGC~gtGG(X~IkGr I "~GCr I~C3r I~ I .C~~~O 
i: M P G L G R R A Q W L C W W W O L L 
271" TGCAGCTGCGGCCCCCCGCCACTGCGGCCCCCTCTGC G TAGCCGCGGCCGCCGCCGGGG~~~C~~CC G 
19" C S C G P P P L R P P L P V A A A A A GVG Q L L G A G G S P 
361: GTGCGCGCTGAGCAGCCACCGCCACAGTCCTCTTCTTCGGGCTTCCTCTATCGGCGGCTCAAGACCCAC GAAG GGGAGATGCAAAAG 
49: V R A E Q P P P Q S S S S G P L Y R R L K T H E K R E M Q K 
451: GAGATCCTGTCGGTGCTGGGGCTCCCGCACAGGCC GCGGCCCCTGCACGGTCTCCAGCAGCCTCA~CCCC~CCCGC~G~G 
79: E I L S V L G L P H R P R P L H G L Q Q P Q P P V L P P Q Q 
541: CAGCAGCAGCAGCAGCAGCAGCAGACGGCCCGC GA GAGCC CCTCCAGGGCGGCTGAAGTCCGCTCCACTCTTCATGCTGGA~TAC 
109" Q Q Q Q Q Q Q 0 T A R E E P P P G R L K S A P L F M L D L Y 
631" AACGCCCTGTCCAATGACGACGAAGAGGATGGGGCATCGGAGGGTGTGGGGCAAGAGCCTGGGTCCCAC AGGGGC~TC~CC~G 
139: N A IL S N D D E E D G A S E G V G Q E [P  G S H G G A S S S Q 
721, CTCAGGcAGCCGTCTCCCGGCGCTGCACACTCCTTGAACCGCAAGAGTCTCCTGGCCCCGGGACCCGGTGG~GGTGCGT~c~C~AcT 
m I 
169" L R Q P S P G A A H S L N R K S L L A P G P G G G A S P L T 
811: AGCGCGCAGGACAGCGCTTTC CTCAAC GACGCGGACATGGTCATGAGCTTTGTGAACCTGGTGGAGTACGACAAG~TCCC~T 
199: S A Q D S A F L N D A D M V M S F V N L V E Y D K E F S P H 
901, CAACGACACCACAAAGAGTTCAAGTTCAACCTATcCCAGATTCcTGAGGGTGAGGCGGTGACGGCTGCTGAGTTCCGCGT•TACAAGGAC 
229: Q R H H K E F K F N L S Q I P E G E A V T A A E F R V Y K D 
991 : TGTGTGGTGGGGAGTTTTAAAAAcCAAACCTTTCTTATCAGCATTTAcCAAGTCTTGCAGGAGCATCAGCACAGAGA~CCTA~T 
259: C V V G S F K N Q T P L I S I Y Q V L Q E H Q H R D S D L F 
1081 : TTGTTGGACACCCGGGTGGTGTGGGCCTCAGAAGAAGGTTGGCTGGAATTTGACATCACAGCAACTA~~~~CCG 
289: L L D T R V V W A S E E G W L E P D I T A T S N L W V V T P 
1171, CAGCACAACATGGGGCTCCAGCTGAGTGTGGTGACTCGGGATGGACTCCACGTCAACCcCCGTGCGGCGGGCCTGGTGGGCAGAGACGGC 
319: Q H N M G L Q L S V V T R D G L H V N P R A A G L V G R D G 
1261, CCTTACGACAAGCAGCCCTTCATGGTGGCCTTCTTCAAGGTGAGCGAGGTCCACGTGCGCACCAC CAGGTCAGCCTCCAGTCGGC GCGG 
349" P Y D K Q P F M V A F F K V S E V H V R T T R S A S S R R RV 
1351: CAGCAGAGTCGCAACCGGTCCAC CCAGTCGCAGGACGTGTCCCGGGGCTCCGGTTCTTCAGACTACAACGGCAGTGAGTTAAAAA~T 
379, Q Q S R N a S T Q S Q D V I  S R G S G S S D Y N G s E L K T [A  
1441- TOC~Oa~OC~TO~'GC~C~TOTO~OC~CCXOOaCCTOOOATOOCAOOACTOO~~CC~~C~C~C~ 
409: C K K H E L Y V S F 0 D L O W Q D W I I A P K O Y A A N Y C 
1531, GATGGAGAGTGTTCCTTCC CACTCAACGCACACATGAATGC CACCAACCAC GCCATTGTACAGACCTTGGTCCACCTTATGAATCCCGAG 
439" D G E C S F P L N A H M N A T N H A I V Q T L V H L M N P E 
1621: TAC GTCCCCAAAC ATGCTGC GCACCAACCAAACTGAAT GC CATCTCGGTTCTTTACTTCGATGATAACTCCAATGTCATCTTGAAAAAG 
469: Y V P K P C C A P T K L N A I S V L Y P D D N S N V I L K K 
1711 : TACAGGAATATGGTCGTGAGAG~TTGTGGTTGCCATTAAgt tgaagctggtgtgtgtgtgtgggtgggggcatggt tc tgcct tggat tc  
499: Y R N M V V R A C G C H * 
1801: c taacaacaacat  ct gcct taaaccacgaacaacagcacagcgaagcgggatggt  gacacacagagggat  cgt gacacgcagacacatct  
1891: ~g~tggtg~tta~c~a~ggagg~ttttatgagga~cttgt~aaggg~ttt~ccagttcctaactgagcagttgctggtctgcaggaa 
1981- gctggaaggct  tgtagt ac aggcct ggaaactgcagt tacctaat gttcgcct cccccaaccccgcccggagtagt  t tt agct tt tagat 
2071: ctag~tgcttgtggtgtaagtaaa~ttgaaggaatattaaatat~tgggttgaaagacccggtggtgg~tc~acag~a~atcccag 
2161, ggagatttttgcagacatccgaatggaggggagaagggcactcttt¢aggttc~attcccagcaagggcagctcacaca~gacctgcagc 
2251- ctggccatcagcaggctctgtggaggtgccttctgtctactgttgtagttacgtgttttgtgttgactctcggtggtgtgagaatgtact 
2341- aatctctgtcaagacaaactgtagcatttccaccccatcctcctccctccctcacagaattc 
Figure 2. Nucleotide and deduced amino acid sequence of composite vgr-1 eDNA. The 5' 851 bp are derived from a BamHI/BspHI genomic 
fragment, and the downstream 1551 bp are from previous vgr-1 eDNA cloning (29). Nueleotide and amino acid numbering is shown in 
the left column. Untranslated nueleotides are in lowercase l ttering. Oligopeptides used for antibody production are boxed, and potential 
N-linked glycosylation sites are underlined. Potential cleavage sites for eliminating the signal sequence (48) and for separating precursor 
from mature domains are marked with inverted arrowheads. The stop codon is marked with an asterisk. The nueleotide and protein sequence 
data reported in this paper will appear in the EMBL Database under the accession umber X80992. 
of cell proliferation both in the presence and absence of se- example, see reference 13), and we reasoned that the con- 
rum (Fig. 4). There were no differences in levels of expres- tinuous release of recombinant vgr-1 by the tumor cells 
sion of collagen I and II, as assessed by immunocytochemis- would allow us to evaluate the biological activity of vgr-1 in 
try and Northern blot analysis (data not shown), vivo. This approach would thus not necessitate he purifica- 
tion of recombinant vgr-1, but would rely on a continuous re- 
Vgr-l-expressing ClIO Cells form Tumors with lease of vgr-1 that was naturally activated and incorporated 
Altered Phenotype into the extracellular matrix. To this end, we injected CHO 
To evaluate the effects of vgrA in vivo, we injected the vgr- or CHO-vgr-1 cells into the fight paraspinous area in the 
1-expressing CHO cells subcutaneously into nude mice. lower lumbar region of nude, athymic mice. Five animals 
Previous studies had shown that CHO cells form localized were injected with the parental cells, and five with the stable 
tumors when injected subcutaneously into nude mice (for an transfected CHO-vgr-1 cells. One animal from each group 
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Figure 3. Characterization f CHO- 
vgr-1 stable transfectants. (A) North- 
ern blot analysis of total RNA from 
CHO (lane 1) and CHO-vgr-1 cells 
(lane 2) after hybridization with vgr-1 
cDNA and stringent washing. The 
positions of 28S and 18S ribosomal 
RNA are marked. (B) Western blot 
analysis of conditioned media from 
CHO (lanes I and 3)and CHO-vgr-I 
cells (lanes 2 and 4) incubated with 
either antisera directed against the 
vgr-1 precursor segment (lanes I and 
2) or mature vgr-I protein (lanes 3 
and 4). Protein standards arenoted. 
(C) Immunostaining of (/) CHO and 
(2) CHO-vgr-I transfectants with 
affinity-purified vgr-1 antibody di- 
rected against the precursor portion 
of the molecule. Bar, 100 sm. 
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Figure 4. Growth rate of CHO vs CHO-vgr-1 transfectants. Cells were grown in either 10% fetal calf serum (A) or in insulin, transferrin, 
and selenium (/3). The growth of CHO cells is represented by the full line with open symbols, and CHO-vgr-1 ceils are noted by the dashed 
line with closed symbols. Three independent plates were grown for each cell type under each condition at each time point, and each plate 
was counted individually three times and then averaged. Each point on the graph represents the average of these readings, with standard 
deviation as noted by the error bars. 
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died from nonspecific causes before visible tumor growth oc- 
curred. After 2 wk, tumors were visible in all mice injected 
with either cell line. In concordance with the in vitro growth 
rate studies, the tumors produced by the parental cells grew 
faster than those from the vgr-l-transfected CHO cells (data 
not shown). After 1 mo, or by the time the tumors reached 
4 cm in largest diameter, the animals were killed and autop- 
sies were performed. 
The tumors produced by both cell types were well ocal- 
ized and encapsulated. However, the tumors had striking 
differences in gross morphology (Fig. 5). The parental cells 
produced tumors with a convoluted surface, and they were 
hemorrhagic, necrotic, and friable (Fig. 5 A). In contrast, he 
CHO-vgr-1 tumors did not have a significant hemorrhagic 
component, had a smooth surface, and were quite dense, 
firm, and fibrotic (Fig. 5 B). 
Histological examination of these tumors further high- 
lighted the differences noted in the gross morphology. He- 
matoxylin and eosin staining of the CHO tumors showed 
nests of tumor cells surrounded by necrotic debris, as well 
as red and white blood cells (Fig. 6 A). Similar nests of tu- 
mor cells were also seen in the CHO-vgr-1 tumors, but there 
were no significant areas of necrosis. Moreover, the tumor 
ceils were encompassed byregions of fibrosis, with signifi- 
cant expansion of surrounding connective tissue (Fig. 6 B). 
The tumors induced by the CHO-vgr-1 cells appeared to con- 
tain a well-developed vasculature, which in turn supported 
the growth and development of an organized tissue mass. 
Bone and Cartilage Formation in rgr-1 Expressing 
CHO Tumors 
Further histological examination of hematoxylin-eosin- 
stained tissue sections from CHO-vgr-1 revealed regions of 
cartilage and bone tissue within portions of the mesenchyme 
in and around the tumors, accounting for ~20% of the tumor 
mass (Fig. 6 C). These areas contained varying amounts of 
cartilage and bone, with some consisting solely of cartilage, 
others containing a mixture of both cartilage and bone, and 
finally, areas corresponding solely to bone. No bone and car- 
tilage tissue was observed in any of the tumors derived from 
the parental CHO cells. 
Figure 5. Gross morphology of tumors produced by CHO or CHO- 
vgr-1 cells. (A) A CHO tumor, with convoluted surface and 
significant hemorrhage, was friable and necrotic. (B) A CHO-vgr-1 
tumor, with smooth surface and only limited hemorrhage, was fi m, 
dense, and fibrotic. Scale bar indicates the size of the tumors. 
To further characterize these areas of bone and cartilage 
formation, we performed several histochemical nd im- 
munohistochemical st ining procedures. InFig. 7, the tumor 
sections were stained with Alcian blue, which binds to 
mucopolysaccharides found in cartilage. The CHO tumor 
sections did not stain with Alcian blue, but only with the 
counterstain, whereas the CHO-vgr-1 tumors contained ex- 
tensive regions of blue staining (Fig. 7, A and B). At higher 
magnification, these areas appeared morphologically as 
chondrocytes or hypertrophic chondrocytes (Fig. 7 C). An 
adjacent section was stained by the von Kossa method, and 
some of these same areas stained black, indicating regions 
of mineralization. Thus, such areas contained hypertrophic 
cartilage that had mineralized; if this tumor had been in- 
cubated longer in vivo, then this area would presumably have 
been replaced by bone. 
To confirm areas of bone formation within the CHO-vgr-1 
tumors, we analyzed ifferent sections using the yon Kossa 
and trichrome staining methods. A  shown in Fig. 8, CHO- 
vgr-1 tumors, but not tumors derived from the parental CHO 
cells, had areas that stained positively in regions that ap- 
peared morphologically as trabecular bone. At a higher 
magnification, we noted the presence of osteoblasts, osteo- 
cytes, and osteoclasts within such areas of trabeeular bone. 
The regions of cartilage and bone were further defined 
with immunohistochemical analyses for collagen II, which 
is specifically deposited in cartilage, and for collagen I and 
osteocalcin, proteins associated with bone. Portions of the 
CHO-vgr-1 tumor stained specifically with the collagen II 
antibody, with such staining apparent incartilage matrix,but 
not in areas of apparent bone formation (Fig. 9 A). No colla- 
gen II staining was detected in the CHO tumors. Other areas 
that appeared histologically as bone were stained with anti- 
bodies for both collagen I and osteocalcin (Fig. 9, B and C). 
No such dual collagen I and osteocalcin staining was seen 
in any region of the CHO tumors. Collagen I staining was 
not confined to bone in the CHO-vgr-1 tumors, but was also 
noted within areas of surrounding connective tissue; wide- 
spread staining was also noted within the CHO tumors in 
regions of necrotic debris. Finally, CHO-vgr-1 tumors also 
had regions that stained with all three antibodies, indicative 
of cartilage adjacent to bone tissue (Fig. 9 D). Collectively, 
these findings uggest that here had been a recapitulation f 
endochondral bone formation within t ese tumors, in which 
a cartilage template formed initially and was eventually 
replaced by bone. 
We postulated that the vgr-1 secreted by the transfected 
CHO cells had induced mesenchymal cells of the host animal 
to differentiate into bone and cartilage. Indeed, mesen- 
chymal cells are known to differentiate into chondroblasts 
and osteoblasts, whereas CHO cells are not known to 
differentiate. To prove this hypothesis, we designed a 
riboprobe for in situ hybridization to distinguish injected 
CHO cells from host mouse cells. Although both t e host 
and transfected CHO cells expressed endogenous dhfr 
mRNA, the CHO cells also overexpressed an additional dhfr 
mRNA derived from the transfected xpression vector (45). 
This latter transcript contained a unique 3' untranslated re- 
gion derived from the hepatitis B surface antigen gene. This 
region served as a riboprobe to specifically identify CHO 
cells within the tumor samples. As seen in Fig. 10 A, the anti- 
sense riboprobe hybridized intensely to the nests of CHO- 
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Figure 6. Haematoxylin a d eosin stain- 
ing of tumors. (A) Section from a CHO 
tumor, showing areas of darker stained 
tumor cells with surrounding hemor- 
rhage (orange) and necrosis (lighter 
stained pink areas). Bar, 200/zm. (B) 
Section from a CHO-vgr-1 tumor, show- 
ing two regions of darker stained tumor 
cells separated by connective tissue. (C) 
Section of CHO-vgr-1 tumor showing 
areas of cartilage (upper left corner of 
figure, large arrow) and bone (smaller 
arrows). Magnification for A and B is 
xl0, and C is ×20. 
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Figure 7. Regions of cartilage within the CHO-vgr-1 tumors. (A) CHO tumor stained with Alcian blue and nuclear fast red counterstain, 
with only the counterstain visualized. CHO cells are present in the upper left corner of the figure, with surrounding necrotic debris and 
red blood cells (tan). Image is seen at ×10. Bar, 200 #tin. (B) ×10 view of CHO-vgr-1 tumor stained with Alcian blue, with marked areas 
of intense blue staining the matrix surrounding chondrocytes. (C) ×20 view of the Alcian blue staining region shown in R Cell morphology 
corresponds tochondrocytes and hypertrophic cbondrocytes. (D) yon Kossa stain of an adjacent section, with black areas corresponding 
to mineralization f some portions of the cartilage. 
vgrol tumor cells, but did not react with the cells in the carti- 
lage and bone tissue and surrounding mesenchyme at the 
tumor periphery. Therefore, the cells within these tissues 
must have arisen from mesenchymal cells of the host animal 
that had been incorporated into the tumor. A low, uniform 
background of nonspecific hybridization was seen using the 
sense strand probe as a negative control (Fig. 10, C and D). 
This conclusion was further strengthened by the positive im- 
munostaining for osteocalcin (Fig. 9). This antibody recog- 
nizes only mouse but not hamster osteocalcin, confirming 
that the bone tissue must have originated from mouse. 
Discussion 
Little is currently known about he function of a distinct sub- 
group of the TGF-~ superfamily consisting of BMP-5, vgr-1/ 
BMP-6, OP-1/BMP-7, and OP-2. We have focused on vgr-1/ 
BMP-6 as a prototype member of this subgroup. The previ- 
ous finding that vgr-1 mRNA is the only TGF-B superfamily 
member localized to hypertrophic cartilage suggests that it 
may play a pivotal role in the transition of cartilage to bone 
during endochondral bone formation. We report here the 
generation of vgr-l-specific antibodies and the subsequent 
immunohistocbemical localiz~ttion of vgr-1 protein to hyper- 
trophic cartilage. Furthermore, we produced stably trans- 
fected CHO cells expressing recombinant vgr-1 protein at 
high levels. Finally, we injected the vgr-l-expressing CHO 
cells into mice to evaluate the effects of continuous release 
of vgr-1 in vivo. In contrast to the nontransfected cells, the 
minors formed by vgr-l-expressing cells contained extensive 
areas of fibrosis, with bone and cartilage formation in a pat- 
tern that seemed to mimic endochondral bone formation. 
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Figure 8. Regions of bone 
within the CHO-vgr-1 tumors. 
(A) von Kossa stain ofCHO- 
tumor, with only background 
nuclear fast red stain visual- 
ized. CHO cells stain pink, 
and they are visualized in the 
left eentrai portion of the fig- 
ure surrounded by necrotic 
debris and red blood cells 
(staining tan). (B) von Kossa 
stain of CHO-vgr-1 tumor, 
with black areas correspond- 
ing to regions of trabecular 
bone. CHO-vgr-1 cells are the 
pink-stained cells onthe left 
side of the figure. (C) Tri- 
chrome stain of CHO tumor 
with no positive staining, and 
only the Weigert bematoxylin 
counterstain is visualized. 
CHO cells are the magenta- 
stained regions onthe upper 
portion of the figure. (D) Tri- 
chrome stain of CHO-vgr-1 
tumor with intense blue stain- 
ing of trabecular bone. CHO- 
vgr-1 ceils are the magenta- 
stained regions in the upper 
left and lower left portions of 
the figure. All images are seen 
at x20. Bar, 100/~m. 
Vgr-1 Expression in Hypertrophic Cartilage 
Previous tudies have localized vgr-1 expression i  the de- 
veloping mouse using both in situ hybridization and im- 
munohistochemistry (21, 29, 50). The former studies estab- 
lished the expression of vgr-1 mRNA in the central nervous 
system, suprabasal layer of the epidermis and other epithelial 
structures, and in hypertrophic cartilage. However, using im- 
munohistochemistry, vgr-1 protein was found only in the 
central nervous ystem and epithelial structures, but not in 
hypertrophic cartilage, leading to the suggestion that the 
mRNA may not be translated in the latter tissue (50). We 
now report hat vgr-1 mRNA is indeed translated into protein 
in hypertophic chondrocytes, asassessed by immunohisto- 
chemical staining using our vgr-1 antibody. The antibody 
staining is highly localized in the matrix surrounding the 
hypertrophic chondrocytes. This staining pattern strongly 
suggests that the secreted vgr-1 has a very limited diffusion 
range and that the hypertrophic cartilage matrix serves as a 
reservoir for this TGF-/~ superfamily member. 
Vgr-1 was immunolocalized to hypertrophic artilage 
solely using an antibody against the mature, carboxy- 
terminal portion of the protein. In contrast, both Wall et al. 
(50) and ourselves were unable to detect protein expression 
in this tissue using an antibody directed against he vgr-1 
precursor segment. The reason for this inability remains un- 
clear. One possibility is that the precursor region has ac- 
quired an altered conformation, either naturally or as a result 
of the treatment procedure, that renders it inaccessible tothe 
antibody. If this were the case, then this modification must 
be different from that in epithelial structures and in the cen- 
tral nervous ystem, where the vgr-1 precursor antibody was 
used successfully. Alternatively, the vgr-1 precursor segment 
may be proteolytically degraded in hypertrophic cartilage. 
This would resemble the proteolytic activation of TGF-/5'I in 
situ after irradiation, which is accompanied by a strong de- 
crease in immunostaining using a precursor-specific anti- 
body (2). Such vgr-1 precursor segment degradation could, 
in turn, provide higher accessibility of mature vgr-1 for its 
receptor, as in the case of TGF-B. 
Recombinant Expression of vgr-1 Protein and 
Biological Activity In Vivo 
To evaluate the biological functions of murine vgr-1, we 
generated an efficient expression plasmid to overexpress 
recombinant protein. CHO cells stably transfected with this 
vector synthesized and secreted high levels of recombinant 
vgr-1 protein, approximately half of which had undergone 
the predicted proteolytic cleavage. The transfected cells grew 
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Figure 9. Immunohistochemistry of 
bone and cartilage in CHO- vgr-1 tu- 
mors. (A) CHO-vgr-1 tumor section 
stained with a collagen II antibody, iden- 
tifying areas of cartilage formation 
(brown). (B) CHO-vgr-1 tumor section 
stained with a collagen I antibody, iden- 
tifying regions corresponding to bone 
(brown). (C) CHO-vgr-1 tumor section 
stained with an osteocalcin antibody, 
identifying regions corresponding to
bone (brown). (D) CHO-vgr-1 tumor 
section that contains an area that ap- 
pears morphologically as bone (/arge 
arrows), and stained with collagen lI an- 
tibody, identifying chondrocytes that are 
adjacent to bone tissue (circular brown 
areas noted by smaller arrows). All 
views are x20. Bar, 100 #m. 
slower than the parental cells, but otherwise xhibited no 
significant differences when characterized in vitro. 
To assay the biological activity of vgr-1 in vivo, we intro- 
duced the CHO-vgr-1 transfectants directly into mice via a 
subcutaneous injection, rather than first purifying recom- 
binant protein from conditioned media of the CHO-vgr-1 
cells. Previous tudies have documented that CHO cells form 
localized tumors when injected subcutaneously (13), and we 
reasoned that the transfected cells would act as a depot 
source of vgr-1 by continuously releasing the recombinant 
protein within the tumor. As expected, injection of the CHO- 
vgr-1 stable transfectants i  nude mice induced tumor for- 
mation, as did the parental cells. However, the CHO-vgr-1 
tumors howed astriking increase in surrounding connective 
tissue and exhibited bone and cartilage formation. Some 
areas howed only cartilage or trabecular bone; others con- 
tained bone intimately associated with adjacent areas of car- 
tilage, or contained areas of mineralized cartilage. Taken 
collectively, these findings suggest recapitulation of en- 
dochondral bone formation, in which a cartilage template is
first formed, and is later replaced by mineralized bone. 
Another fundamental difference between the tumors in- 
duced by the CHO cells as opposed to the CHO-vgr-1 trans- 
fectants was that the parental cells produced tumors lacking 
any organized vascular supply. Thus, overgrowth of these 
cells resulted in hemorrhagic, necrotic debris, and the 
tumors were unable to support development of an organized 
tissue mass. By contrast, the CHO-vgr-1 cells formed tumors 
with a well-delineated vascular supply, and thereby sup- 
ported development of well-organized tumor masses, with 
profusion of connective tissue and differentiation f cartilage 
and bone. During endochondral bone formation, angiogene- 
sis in hypertrophic cartilage iscritical for mineralization a d 
subsequent bone formation. The endogenous localization of 
vgr-1 to the site of angiogenesis in hypertrophic cartilage 
suggests hat this factor may mediate n w vessel formation. 
The cellular elements of fibrosis and endochondral bone 
formation within the CHO-vgr-1 tumors did not appear to 
have arisen directly from the CHO cells, but instead from the 
effects of secreted vgr-1 on surrounding host mesenchymal 
cells. Several lines of evidence support this hypothesis. First, 
the connective tissue, cartilage, and bone did not hybridize 
with a riboprobe that specifically identified the transfected 
CHO cells. Second, CHO cells are not known to differentiate 
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Figure 10. In situ hybridizations to define CHO cells within the tumors. (A) Dark-field microscopy of section from a CHO-vgr-1 tumor 
that has been hybridized with an antisense riboprobe directed against the 3' untranslated region of hepatitis B surface antigen. This probe 
corresponds to part of the dhfr transcript generated from the expression vector transfected into the CHO cells, and most importantly, it
identifies an mRNA specific to the CHO cells. White grains correspond to probe that has hybridized to CHO-vgr-1 cells. Note that the 
bone and surrounding mesenchyme lack significant hybridization. (B) Bright-field view of section shown in A. The darker staining regions 
correspond to trabecular bone. (C) Dark-field microscopy of section from a CHO-vgr-1 tumor that has been hybridized with a sense 
riboprobe to hepatitis B surface antigen, serving as a negative control. A low level of background hybridization is shown uniformly through- 
out the section. (D) Bright-field view of the section shown in C. All views are ×10. Bar, 200 t~m. 
in vitro or in vivo, making it unlikely that the vgr-l-trans- 
fected CHO cells differentiated into osteoblasts or chondro- 
cytes. In fact, the transfected cells exhibited no such differen- 
tiation when evaluated in vitro. Third, the bone matrix 
within the CHO-vgr-I tumors stained positively using a 
monoclonal antibody specific for mouse osteocalcin that 
does not cross-react with rat or hamster osteocalcin, further 
substantiating our conclusion that the ectopic bone did not 
originate from hamster cells. Finally, conditioned media 
from CHO-vgr-1 cells, but not from CHO cells, also induced 
ectopic bone formation when injected intramuscularly (Kirk, 
M., and S. E. Gitelman, unpublished results). 
Vgr-1 secreted by the CHO-vgr-1 tumors appeared to have 
acted only locally within these animals. We have not devel- 
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oped an assay to measure serum levels of vgr-1, and thus have 
not formally tested if these animals contained significant cir- 
culating levels of this factor. However, analysis of long bones 
near the site of the tumor showed no changes as compared 
to those of the control animals, and extensive autopsies re- 
vealed no significant changes in any other major organs. 
Possible Mechanisms of Vgr-1 Action 
Our findings indicate that recombinant vgr-1 protein was 
sufficient to induce fibrosis and bone and cartilage formation 
in vivo. Yet, the complexity of such an in vivo study makes 
it difficult o pinpoint he specific primary actions directly 
attributable tovgr-1, as opposed to secondary actions medi- 
ated through other factors. One important function of vgr-1, 
at least in the context of this study, may be as a chemoattrac- 
tant to bring various cell types to the tumor, including 
mesenchymal precursors. Alternatively, vgr-1 may act as a 
mitogen to increase the number of various host cells already 
present in or near the tumor. In fact, several other members 
of the TGF-/~ superfamily can serve as chemoattractants or 
mitogens for a variety of cell types, including mesenchymal 
cells, fibroblasts, osteoblasts, neutrophils, monocytes, epi- 
thelial cells, and endothelial cells (for examples, see refer- 
ences 19, 39, 42, 58). The most widely studied factor from 
this standpoint has been TGF-/31. Injection of recombinant 
TGF-/31 into newborn mice and chicken chorioallantoic 
membrane induces a granulation tissue response, with 
inflammation, fibrosis, and angiogenesis (42, 58). The 
hypercellular lesions in the chicken study resulted not from 
cellular proliferation, but from enhanced cell migration 
through chemotaxis (58). Only limited studies have been 
conducted with the BMPs, with BMP-3 and BMP-4 
chemotactic for monocytes in vitro (9). Further studies are 
needed to determine if vgr-1 also serves as a chemoattractant 
and/or mitogen, and if vgr-l's actions in this regard are distin- 
guishable from that of other members of the TGF-/~ super- 
family. Vgr-1 does not alter the growth rate of two pluripotent 
mesenchymal cell lines in vitro, suggesting that it may not 
function as a mitogen in vivo (Gitelman, S. E., J. Q. Ye, and 
R. Derynck, unpublished results). 
The influx of additional host cells into the tumor site adds 
another layer of complexity incharacterizing the primary ac- 
tions of vgr-1. Each of these cell types may release additional 
factors into the tumor area, such as other TGF-/3 superfamily 
members, local growth factors, cytokines, or various ex- 
tracellular matrix proteins. Vgr-1 may act in a paracrine fash- 
ion to stimulate production and release of such factors from 
these neighboring host cells, and may also act in concert with 
these factors to induce the fihrotic hanges and endochondral 
bone formation oted within the CHO-vgr-1 tumors. 
Role of TGF-[3 Superfamily inEndochondral 
Bone Formation 
Several members of the TGF-/3 superfamily have now been 
shown to induce endocbondral bone formation when in- 
jected in vivo. TGF-/31 and TGF-/32 induce endochondral 
bone formation when introduced subperiosteally or at a frac- 
ture site, but not at a site that is not anatomically connected 
to bone (4, 23, 32, 35). In contrast, BMP-2, -3, -4, -7, and 
now vgr-1 have the ability to induce ectopic bone formation 
when injected intramuscularly or subcutaneously (17, 28, 43, 
51, 54). Such findings uggest that these BMPs may act on 
a less differentiated mesenchymal precursor than TGF-~ dur- 
ing endochondral bone formation. The findings also imply 
functional redundancy among these factors, yet specificity 
appears to reside in the spatially and temporally distinctive 
patterns of their expression (for an example, see reference 31). 
In all other studies, a recombinant factor has been intro- 
duced in vivo as a purified protein delivered within an inert 
carrier. Our study is the first to have been conducted with 
direct injection of CHO cells that continuously release 
recombinant protein. As a result, comparison of vgr-rs 
potency with that of the other TGF-/~ related factors is not 
yet possible, and awaits purification of recombinant vgr-1 
from conditioned media. 
Definition of the specific role of individual TGF-/~ super- 
family members in endochondral bone formation awaits 
more refined studies, both in vitro and in vivo. The present 
study entailed overexpression f vgr-1 in an ectopic location, 
and demonstrated that vgr-1 had the ability to initiate mesen- 
chymal differentiation along the endochondral bone pathway. 
To further define the function of this factor during normal 
bone and cartilage development, i  will be important to 
manipulate the expression of vgr-1 and its receptor within 
hypertrophic cartilage, vgr-rs endogenous site of production. 
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